Markets:

Overview

News

Currencies

International

Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

24.48 -1.07 (-4.21%)

Streaming Delayed Price Updated: 11:46 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Here's Why This Biotechnology Skyrocketed by 439% in December ↗

Today 6:01 EST

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment.

Via The Motley Fool

On Friday, there are stocks with unusual volume. Let's take a look. ↗

December 05, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 04, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗

December 04, 2025

DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

Via Stocktwits

‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% ↗

November 24, 2025

Via Stocktwits

Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection ↗

November 10, 2025

Via Stocktwits

Tesla Chair Declares Start Of 'Whole New Book' As Musk's 423 Million Share Award Is Locked In — All Hope Pinned On Robotaxi, Optimus ↗

November 10, 2025

Via Stocktwits

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win ↗

December 03, 2025

Capricor’s positive HOPE-3 results prompted Shkreli to call his short thesis a “bad call” after the therapy showed statistically significant skeletal and cardiac benefits.

Via Stocktwits

Why Did Capricor Therapeutics Stock Skyrocket Today? ↗

December 03, 2025

The HOPE-3 study, involving 106 participants across 20 U.S. centres, delivered strong signals of benefit for muscle and heart function.

Via Stocktwits

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Preview: Capricor Therapeutics's Earnings ↗

November 07, 2025

Via Benzinga

Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder ↗

September 25, 2025

Via Stocktwits

Get insights into the top gainers and losers of Wednesday's pre-market session. ↗

December 03, 2025

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Nasdaq, S&P 500 Futures Point To Steady Open: Why CAPR, MRVL, AEO, GTLB, CRWD Are On Traders' Radar ↗

December 03, 2025

After a volatile start to the week, markets are showing signs of stabilization.

Via Stocktwits

Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout ↗

December 01, 2025

Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks.

Via Stocktwits

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Top movers in Monday's session ↗

November 24, 2025

Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗

November 10, 2025

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.

Via Benzinga

Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback ↗

November 04, 2025

Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.

Via Stocktwits

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Why Capricor Therapeutics Stock Is Surging Today ↗

September 25, 2025

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics.

Via Benzinga

Gapping stocks in Thursday's session ↗

September 25, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Via Chartmill

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

September 16, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

September 15, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 15, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 15, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit

September 14, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Lawsuit - CAPR

September 12, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.